Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential

The promising anti-inflammation target could be the next big thing in cardiovascular and other diseases.

By Alexandra Pecci • Jan. 29, 2026

Has Novavax cracked the code for survival in the vaccine arena?

The company’s new partnership with Pfizer is worth up to $530 million — and could be just the beginning.

By Meagan Parrish • Jan. 28, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

A potential gene therapy for heart failure is an approach decades in the making

Medera’s mid-stage heart failure gene therapy leverages a “master switch” that could widen the aperture of genetic medicine.

By Michael Gibney • Jan. 27, 2026

Big Pharma shops Chinese biotechs to stock GLP-1 pipelines

Novo, Regeneron and Pfizer all landed weight loss deals with China-based companies last year.

By Alivia Kaylor • Jan. 23, 2026

Cancer R&D is thriving. Here are the areas to watch in 2026.

ADCs, radioligand therapies and multispecifics are leading the way in cancer innovation.

By Kelly Bilodeau • Jan. 21, 2026

Texas, N. Carolina, Ohio, Pennsylvania — where pharma manufacturing investments have surged

Pledged projects have landed in a handful of hotspots while giving rise to potential new hubs across the U.S.

By Alexandra Pecci • Jan. 20, 2026

The clinical candidates pharma execs are tracking

Industry leaders at JPM this week revealed which up-and-coming assets they’re watching from other companies in oncology and neuroscience.

By Meagan Parrish • Jan. 16, 2026

3 positive trends for Massachusetts’ biopharma sector

Despite a rocky landscape for the biotech industry nationally, Massachusetts has shown innovation growth and stronger funding than expected, which could bode well for the future.

By Michael Gibney • Jan. 13, 2026

A biotech’s snakebite pill is drawing the US military’s interest

Backed by the Department of Defense, Ophirex is developing the first oral snakebite treatment, making on-the-ground treatment possible for the first time.

By Alexandra Pecci • Jan. 13, 2026

What Sanofi’s multiple sclerosis troubles could mean for the space

The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug class. 

By Kelly Bilodeau • Jan. 12, 2026

PharmaVoice’s Crystal Ball: What’s next for AI and drug R&D

Industry execs foresee drug innovation and AI breakthroughs in 2026.

By Meagan Parrish • Jan. 9, 2026

Billionaire Sean Parker has already shaken up cancer R&D. Can his nonprofit fix the funding gap?

The entrepreneur’s cancer institute is striving to be the financial glue for an embattled research community while going beyond therapies and creating cures.

By Michael Gibney • Jan. 8, 2026

5 FDA drug approvals to watch in 2026

Potential blockbusters and root-cause treatments from Eli Lilly, Merck, Takeda and others could get a regulatory nod this year.

By Alexandra Pecci • Jan. 7, 2026

C-suite priorities give a sneak peek into AI’s pharma future

While some are still leery of the technology, leaders see AI as a way to boost efficiency and cut costs.

By Kelly Bilodeau • Jan. 7, 2026

3 of China’s most innovative pharma companies

The top Chinese drugmakers succeeding in both innovation and business savvy.

By Kelly Bilodeau • Jan. 5, 2026

Beyond Botox: AbbVie’s push for broader gains in neurotoxin R&D

The large pharma is advancing two next-generation neurotoxins in both the therapeutic and aesthetic spaces.

By Alexandra Pecci • Dec. 23, 2025

Biopharma CEO optimism is wavering in the US

The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.

By Kelly Bilodeau • Dec. 22, 2025

Biogen’s CIO is betting on a tech and AI overhaul to ‘pave the highways’ toward growth

Guy Hadari discusses how his role has changed with the introduction of new technologies, and what that means for Biogen’s future.

By Michael Gibney • Dec. 19, 2025

The leading GLP-1 contenders in pharma’s race for an obesity pill

Recent mid-stage readouts reveal how the market for an oral weight loss drug could take shape. 

By Alivia Kaylor • Dec. 18, 2025

3 key takeaways from the FDA’s new animal testing guidance

The agency’s moves to end animal testing are “not a fluke.” Here’s what drugmakers need to know about where it goes from here.

By Alexandra Pecci • Dec. 17, 2025

How the FDA could soon upend vaccine trials

Vaccinemakers should be prepared to pivot to meet new requirements by ensuring strong communication.

By Kelly Bilodeau • Dec. 17, 2025

Amylyx pins its next hopes on a niche drug in the obesity space

A lot is riding on Amylyx’s late-stage candidate for post-bariatric hypoglycemia.

By Meagan Parrish • Dec. 12, 2025

Pharma’s top deals in 2025

The year’s three largest acquisitions signal where pharma is willing to pay big for promising candidates.

By Michael Gibney • Dec. 11, 2025

Another genetic testing company? Why a different approach could boost drug predictions and R&D.

Genetic tests could soon play a larger role in clinical trials and predicting adverse events.

By Alexandra Pecci • Dec. 10, 2025

How Lilly uses Big Pharma heft to lift up-and-coming biotechs

With great power comes great responsibility, and Eli Lilly is employing financial success and technical know-how to give smaller biotechs a leg up.

By Michael Gibney • Dec. 9, 2025